Chiron Capital Management, LLC Aurinia Pharmaceuticals Inc. Transaction History

Chiron Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 18, 2022	SELL	$10.05 - $22.48 $102,510 - $229,296	-10,200 Closed	0 $0
Q4 2021 Jan 18, 2022	SELL	$17.78 - $33.08 $58,674 - $109,164	-3,300 Reduced 24.44%	10,200 $233,000
Q3 2021 Oct 21, 2021	BUY	$10.93 - $23.55 $18,581 - $40,035	1,700 Added 14.41%	13,500 $299,000
Q2 2021 Jul 20, 2021	BUY	$10.0 - $14.52 $6,920 - $10,047	692 Added 6.23%	11,800 $153,000
Q1 2021 May 18, 2021	BUY	$12.3 - $18.73 $136,628 - $208,052	11,108 New	11,108 $144,000
Q4 2020 Mar 05, 2021	SELL	$12.94 - $16.05 $125,518 - $155,685	-9,700 Closed	0 $0
Q3 2020 Nov 19, 2020	BUY	$13.19 - $16.66 $127,943 - $161,602	9,700 New	9,700 $143,000

189

56.5M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.02B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Chiron Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Chiron Capital Management, LLC with notifications on news.